Abstract:Background: The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms underlying their intracellular spread are still being elucidated, targeting the extracellular space has emerged as a potential therapeutic approach. The glymphatic system, a brain-wide pathway responsible for clearing extracellular metabolic waste from the central nervous system, has gained attention as a promising target for removing these toxic proteins. Methods: In this study, we investigated the impact of long-term modulation of glymphatic function on tau aggregation and spread by chronically treating a mouse model of tau propagation with a pharmacological inhibitor of AQP4, TGN-020. Thy1-hTau.P301S mice were intracerebrally inoculated with tau into the hippocampus and overlying cortex, and subsequently treated with TGN-020 (3 doses/week, 50 mg/kg TGN-020, i.p.) for 10-weeks. During this time, animal memory was studied using cognitive behavioural tasks, and structural MR images were acquired of the brain in vivo prior to brain extraction for immunohistochemical characterisation. Results: Our findings demonstrate increased tau aggregation in the brain and transhemispheric propagation in the hippocampus following the inhibition of glymphatic clearance. Moreover, disruption of the glymphatic system aggravated recognition memory in tau inoculated mice and exacerbated regional changes in brain volume detected in the model. When initiation of drug treatment was delayed for several weeks post-inoculation, the alterations were attenuated. Conclusions: These results indicate that by modulating AQP4 function and, consequently, glymphatic clearance, it is possible to modify the propagation and pathological impact of tau in the brain, particularly during the initial stages of the disease. These findings highlight the critical role of the glymphatic system in preserving healthy brain homeostasis and offer valuable insights into the therapeutic implications of targeting this system for managing neurodegenerative diseases characterized by protein aggregation and spread.

Interaction of Tau with G-Protein-Coupled Purinergic P2Y12 Receptor by Molecular Docking and Molecular Dynamic Simulation

G-protein coupled receptors regulates Tauopathy in neurodegeneration

Purinergic Receptor P2Y12-Mediated Tau Internalization in Microglia

Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation

Microglia undergoes chemokine receptor, CX3CR1-mediated internalization of extracellular Tau

Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study

Microglial purinergic signaling in Alzheimer's disease

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology

Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

Tau and Neuroinflammation in Alzheimer’s Disease: Interplay Mechanisms and Clinical Translation

Interaction Between A Beta And Tau In The Pathogenesis Of Alzheimer'S Disease

Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease

Characterization of Phosphorylated Tau-Microtubule complex with Molecular Dynamics (MD) simulation

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease

Influence of Tau on Neurotoxicity and Cerebral Vasculature Impairment Associated with Alzheimer's Disease

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Tau Protein Associated Inhibitors in Alzheimer Disease

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies